Conference Reports for NATAP

Back

AASLD The Liver Meeting Washington, DC November 4-8, 2022   This information is brought to you by NATAP and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting® or The Liver Meeting Digital Experience ™     Time from HCV testing to subspecialty care linkage and DAA initiation in the Philadelphia jail system - (12/13/22)   Routine opt out hepatitis C testing upon intake in the Philadelphia jail system - (12/13/22)   3 Hot HCV Posters: Fatty Liver in HCV cured; Cannabis Slows Liver improvement; Non-invasive HCC prediction test; - (11/30/22)   NEGATIVE IMPACT OF CANNABIS CONSUMPTION ON THE REGRESSION OF THE HEPATIC FIBROSIS AFTER SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH DIRECT ACTING ANTIVIRALS - (11/30/22)   Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results - (11/29/22)   HCV PI vs Non-PI DAA in Advanced Cirrhosis - Outcomes Real-World REAL-C study - (11/29/22)   HCC Risk in HCV After SVR in Cirrhosis or No Cirrhosis - (11/29/22)   Low level of hepatitis B viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis - (11/28/22)   Profile of HBV DNA integration in the natural history of chronic hepatitis B - (11/28/22)   Comparable outcomes between immune-tolerant and active phases in non-cirrhotic chronic hepatitis B: a meta-analysis - (11/28/22)   Screening, linkage, to care and treatment of chronic hepatitis C infection in high-risk populations in Hong Kong - (11/28/22)   An Innovative Model to Eradicate HCV in Undocumented Migrants and Low-Income Refugees in Italy - (11/28/22)   Models to Eliminate HCV in the USA: A Multisite Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The HERO Study - (11/28/22)   Real-World Treatment Outcome with Protease Inhibitor (PI) vs Non-PI Direct Acting Antivirals (DAAs) in advanced HCV Cirrhosis: A REAL-C study - (11/28/22)   Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 - (11/28/22)   Topline Results From a New Analysis of the REGENERATE Trial of Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis - (11/28/22)   Clinical and Histologic Factors Associated with Discordance Between Steatosis grade Derived From Histology Versus MRI-PDFF in Patients with NAFLD - (11/22/22)   Increase in Liver Stiffness Measurement (Fibroscan) by Vibration-Controlled Transient Elastography is Associated with Poor Clinical Outcomes in NAFLD - (11/22/22)   MEFIB-Index and MAST-score in assessment of hepatic decompensation in NAFLD- an individual -patient data meta-analysis - (11/22/22)   2 New NASH Drugs in Development - (11/22/22)   Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) - press release - (11/22/22)   PXL065 (DEUTERIUM-STABILIZED R-ENANTIOMER OF PIOGLITAZONE) REDUCES LIVER FAT CONTENT AND IMPROVES LIVER HISTOLOGY WITHOUT PPARy -MEDIATED SIDE EFFECTS IN PATIENTS WITH NASH: ANALYSIS OF A 36 WEEK PLACEBO-CONTROLLED PHASE 2 TRIAL (DESTINY1) - (11/22/22)   The bispecific anti-FGFR1/KLB agonist antibody bFKB1 attenuates non-alcoholic steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice - (11/22/22)   Hepatocellular Carcinoma: State of the Art - missing is & Post HCV Cure Surveillance in Patients with Cirrhosis ! - (11/21/22)   Updated Practice Guidance Fatty Liver, NAFLD State of The Art New Practice Guidelines for NAFLD - (11/21/22)   HIGHER MORTALITY AMONG LEAN VERSUS NON- LEAN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE DESPITE LOWER INCIDENCE OF CIRRHOSIS AND CARDIOVASCULAR DISEASE - (11/21/22)   PREVALENCE OF NAFLD, ADVANCED FIBROSIS, CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN PROSPECTIVELY ASSESSED PATIENTS WITH TYPE 2 DIABETES: A PROSPECTIVE STUDY - (11/21/22)   FIBROSIS PROGRESSION RATE AMONG DIABETIC VERSUS NON- DIABETIC PATIENTS WITH BIOPSY- PROVEN NONALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER PROSPECTIVE STUDY - (11/21/22)   Effect of DAA treatment on extrahepatic manifestations incidence: a population-based study in British Columbia, Canada - (11/21/22)   THE AGILE 3+ AND 4 SCORES MOST ACCURATELY PREDICT MAJOR ADVERSE LIVER OUTCOMES AND DEATH COMPARED TO LIVER STIFFNESS MEASUREMENT AND FIBROSCAN- AST SCORE - (11/17/22)   CORRELATES OF HCV REINFECTION AMONG ACTIVE DRUG USERS - (11/17/22)   AN INNOVATIVE MODEL TO ENSURE ACCESS TO HCV TREATMENT AMONG VULNERABLE INNER CITY RESIDENTS IN COVIDWORLD - (11/17/22)   HCV TREATMENT AMONG FENTANYL USERS: TOWARD UNIVERSAL ACROSS TO ANTIVIRAL THERAPY - (11/17/22)   The impact of direct-acting antiviral treatment for HCV on hepatocellular carcinoma risk in a large population-based cohort study - (11/17/22)   Tenofovir-DF Therapy Prevents Hepatitis B Vertical Transmission in Highly Viremic Mothers Without HBV Immunoglobulin for Infants - (11/17/22)   Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/15/22)   A National Plan to Eliminate Hepatitis C, White House - (11/14/22)   HCV Elimination Review: Target PWUDs for Treatment - EXCELLENT CURE RATES DESPITE INCREASING COMPLEXITY OF PEOPLE WHO USE DRUGS: FINAL CLINICAL OUTCOMES FROM THE ITTREAT HCV SERVICE - (11/14/22)   Use of Psychiatric Medication and Drug-Drug Interactions in Patients with HCV Infection Treated with Pangenotypic Direct-Acting Antivirals - (11/14/22)   Risk factor of hepatocellular carcinoma occurrence after sustained virologic responses in hepatitis C virus patients without advanced liver fibrosis - (11/14/22)   Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection - (11/14/22)   Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/14/22)   Impact of Reflex Testing on the Delta Hepatitis Disease Burden in France - (11/14/22)   Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/14/22)   OVERCOMING BARRIERS TO CARE FOR DELTA INFECTED PATIENTS - (11/14/22)   Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/14/22)   Socioeconomic Determinants of Health in Metabolic Dysfunction-associated Fatty Liver Disease - (11/14/22)   Pediatric Non-Alcoholic Fatty Liver Disease: low resource neighborhoods may increase risk - (11/14/22)   Combination Therapy With Cilofexor and Firsocostat Improves Plasma Fibrosis Biomarkers in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (11/14/22)   PEDIATRIC NON- ALCOHOLIC FATTY LIVER DISEASE: RESIDING IN LOW RESOURCE NEIGHBORHOODS MAY INCREASE RISK - (11/14/22)   Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/11/22)   Extension of Bulevirtide Monotherapy to 72 Weeks in HDV Patients with Compensated Cirrhosis: Efficacy and Safety From the Italian Multicenter Study (HEP4Di) Interim Analysis - (11/11/22)   Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study - (11/11/22)   Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model - (11/11/22)   Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy - (11/11/22)   Novel Anti-HBV Agent (VIR-2218) Aims for Functional Cure With PEG-IFN - Mark Mascolini (11/11/22)   Anti-HBV Therapy at or Before HCC Diagnosis Improves Survival, only 37% received therapy - Mark Mascolini (11/11/22)   GS-2829 and GS-6779 HBV therapeutic vaccine generates robust, polyfunctional, genotype cross-reactive CD8 T cell responses accompanied by high titers of anti-HBsAg antibodiess - (11/11/22)   Low Level of HBV Viremia Increases Risk of HCC in Patients with Untreated Compensated Cirrhosis - (11/11/22)   Preclinical characterization of a novel liver-focused small molecule efficiently inhibiting hepatitis B virus by activating type I interferon signaling - (11/11/22)   Preclinical Characterization of a Novel Class of Highly Potent Small Molecule Hepatitis B and D Virus Entry Inhibitors - (11/11/22)   Young Recent Drug Injectors Run High HCV Reinfection Risk in BC - (11/11/22)   Cirrhosis Linked to More Than Doubled Odds of Severe COVID - Mark Mascolini (11/10/22)   HDV Patient Perspective: The Impact of Disease and Current Unmet Needs - (11/10/22)   Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study - (11/10/22)   Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial - (11/10/22)   Preliminary 48-week Safety and Efficacy Data of VIR-2218 Alone and in Combination With Pegylated Interferon Alfa in Participants With Chronic HBV Infection - (11/10/22)   Updated evaluation of global progress towards HBV and HCV elimination, preliminary data through 2021 (not good) - (11/10/22)   Liver-Related Mortality Soared in US After COVID-19 Arrived - Mark Mascolini (11/10/22)   Viral Sequence Analysis of Not-currently Treated Chronic Hepatitis B Patients Enrolled in the REEF-1 Study and Impact of Baseline Nucleotide Polymorphisms in the Small Interfering RNA JNJ-3989 Trigger Target Regions on Viral Antigen Declines - (11/10/22)   RNA LAUNCH SYSTEM ENABLES IN VITRO EVALUATION OF BEPIROVIRSEN EFFICACY AGAINST HBV VARIANTS - (11/10/22)   HBV DNA and HBsAg loss with bepirovirsen monotherapy in patients with chronic hepatitis B infection not on nucleos(t)ide analogue therapy: B-Clear study end-of-study results - (11/10/22)   Efficacy and Safety of siRNA JNJ-73763989, Capsid Assembly Modulator JNJ-56136379, Nucleos(t)ide Analog, and Pegylated Interferon Alpha-2a for the Treatment of Chronic Hepatitis B: Week 24 Results From the Phase 2 PENGUIN Study - (11/10/22)   Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: Follow-up week 48 end of study results from REEF-2 - (11/10/22)   Bepirovirsen (BPV) in patients with chronic hepatitis B virus (HBV) infection controlled by nucleos(t)ide analogue therapy: HBV DNA and HBsAg loss 6 months after end of BPV treatment (B-Clear study) - (11/10/22)   HBV Therapy Slices HCC Risk in HBV's Indeterminate Phase - Mark Mascolini (11/10/22)   Characteristics of Chronic Hepatitis B Patients in a 20-Year, Real-World Study of Treatment Patterns in a US Health Care Delivery System - (11/10/22)   Metabolic Comorbidities Tied to Shorter HCC-Free Survival With HBV - Mark Mascolini (11/10/22)   CHANGES IN MORTALITY DUE TO CHRONIC LIVER DISEASES (CLD) DURING THE COVID- 19 PANDEMIC: DATA FROM THE UNITED STATES' NATIONAL VITAL STATISTICS SYSTEM - (11/10/22)   NAFLD Is Independent Kidney Disease Risk Factor in People With Cirrhosis - Mark Mascolini (11/09/22)   Over 90% at Risk for Fibrotic NASH Don't Need Liver Specialist - (11/09/22)   Higher Fibrosis Progression Rate in NAFLD Group With vs Without Diabetes - Mark Mascolini (11/09/22)   Bulevirtide, with or without peg- interferon, in HDV infected patients in a real-life setting. two-year results from the French multicenter early access program - Mark Mascolini (11/09/22)   Benefit of regular screening for hepatitis delta and subsequent cirrhosis among chronic hepatitis B carriers - (11/09/22)   Estimating Hepatitis Delta Prevalence Among High-Risk Populations (HIV, MSM, PWID) in the United States: A Systematic Review - (11/09/22)   Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)   Increasing time since eradication of HCV is independently associated with a lower risk of HCC - (11/09/22)   Glecaprevir/Pibrentasvir (G/P) and Ezetimibe for 8 Days Should Be the New Standard of Care With 100% Efficacy to Prevent Chronic HCV Infection in Non-liver Solid Organ Transplant (Sot) Recipients of HCV-VIREMIC Grafts - (11/09/22)   Patients with chronic hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3 - (11/09/22)   Effectiveness of ReLink initiatives to re-engage diagnosed-but-untreated HCV-positive patients with direct-acting antiviral treatment Effectiveness of ReLink initiatives to re-engage diagnosed-but-untreated HCV-positive patients with direct-acting antiviral treatment - (11/09/22)   The Kentucky Viral Hepatitis Treatment Project (KeY Treat): Preliminary Outcomes from a Phase 4 Clinical Trial in Rural Appalachia - (11/09/22)   HCV Treatment Rates Decreased During COVID: CHARACTERISTICS AND TREATMENT RATE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN THE DAA AND COVID- 19 ERAS IN THE UNITED STATES - (11/09/22)   Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)   Bulevirtide Monotherapy Is Safe and Well Tolerated in Patients With Chronic Hepatitis D (CHD): An Integrated Safety Analysis of 48-Week Data - (11/09/22)   The Delta Delta: Gaps in Screening Patterns, Patient Assessment and Clinical Outcomes in Hepatitis D Virus Infection - (11/09/22)   HDV Prevalence Ranges Widely in US High-Risk Groups: Newer Data Needed - Mark Mascolini - (11/09/22)   ULTRA- SHORT COURSE GLECAPREVIR/PIBRENTASVIR WITH EZETIMIBE IN THE PREVENTION OF HEPATITIS C (HCV) TRANSMISSION FROM HCV- POSITIVE ORGAN DONORS TO HCV- NEGATIVE RECIPIENTS: ONGOING EXPERIENCE - (11/08/22)   EARLY INITIATION OF GLECAPREVIR AND PIBRENTASVIR AFTER TRANSPLANTATION OF HCV- VIREMIC INTO HCV- UNINFECTED KIDNEY TRANSPLANT RECIPIENTS RAPIDLY NORMALIZES HCV- INDUCED ALTERATIONS IN THE SOLUBLE INFLAMMATORY MILIEU - (11/08/22)   CASCADE OF CARE FOR CHRONIC HCV INFECTION IN A LARGE HOMELESS METROPOLITAN POPULATION - (11/08/22)   HCV Universal EHR Prompt Successfully Increases Screening, Highlights Potential Disparities - (11/08/22)   EHR HCV Screening - OPTIMIZING HIGH- RISK HEPATITIS C VIRUS (HCV) IDENTIFICATION BY THE INCLUSION OF STRUCTURED, SEMI- STRUCTURED AND FREE- TEXT ELECTRONIC HEALTH RECORD DATA - (11/08/22)   HEPATITIS C VIRUS PREVALENCE AND OUTCOMES AMONG PREGNANT WOMEN WHO INJECT DRUGS - (11/08/22)   67% Remain Untreated - Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - (11/08/22)   Under Two Thirds With Viremic HCV and Insurance Get DAAs in US - Mark Mascolini (11/08/22)   Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir - (11/08/22)   Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) - (11/08/22)   The Incidence of Chronic HBV by Age, 2022 - (11/08/22)   Reduction in Hepatitis B Viral DNA and Hepatitis B Surface Antigen Following Administration of a Single Dose of VIR-3434, an Investigational Neutralizing Monoclonal Antibody: First Experience in a Population With Viremia - (11/08/22)   Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial - (11/08/22)   CURE OF HEPATITIS DELTA INFECTION FOLLOWING 3 YEARS OF BULEVIRTIDE MONOTHERAPY IN A PATIENT WITH COMPENSATED ADVANCED CIRRHOSIS - (11/08/22)   Assembly Biosciences Presents New Data at AASLD The Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV 'ABI-4334' - (11/08/22)   Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting - (11/08/22)   Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD's The Liver Meeting 2022 - (11/08/22)   Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022 - (11/08/22)   Utility of FIB-4, MRE, MRI-PDFF, & FibroScan to Identify Patients With At-risk F2-F3 NASH Based on Screening Data From a 2000 Patient Biopsy-Confirmed Cohort of Resmetirom Phase 3 Clinical Trial (MAESTRO-NASH) - (11/08/22)   A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients With Well-Compensated NASH Cirrhosis - (11/08/22)   Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - 67% Untreated - (11/07/22)   FINAL ANALYSIS OF THE GRAND PLAN STUDY: EFFICACY OF 8 weeks GLECAPREVIR/PIBRENTASVIR (G/P) FOR HCV- INFECTED PEOPLE WHO USE DRUGS (PWUD) DISENGAGED FROM HEALTH CARE: A SYSTEMATIC APPROACH TO ENGAGEMENT AND HCV TREATMENT - (11/07/22)   Early initiation of glecaprevir and pibrentasvir after transplantation of HCV-viremic into HCV-uninfected kidney transplant recipients rapidly normalizes HCV-induced alterations in the soluble inflammatory milieu - (11/07/22)   An HCV transmission model for evaluating complex treatment policies in people who inject drugs (PWID), prisoners, and the general population - (11/07/22)   Estimating the HCV treatment reach in high-risk groups in order to meet 2030 WHO elimination targets - (11/07/22)   High HCV SVR in Rural US Group With Heavy Use of Opioids, Other Drugs - Mark Mascolini (11/07/22)   Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week-48 Results From an Integrated Analysis - (11/07/22)   Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/07/22)   Population adjusted prevalence of hepatitis Delta virus in 16 countries and territories - (11/07/22)   HDV Load Drops, Liver Markers Improve With Bulevirtide for 48 Weeks - Mark Mascolini (11/07/22)   BARRIERS TO HEPATITIS DELTA SCREENING: THE POINT OF VIEW OF FRENCH BIOLOGISTS - (11/07/22)